BIM
BCRX icon

Bogle Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bogle Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,078,345
Closed -$9.06M – 299
2017
Q1 		$9.06M Buy
+1,078,345
New +$7.5M 0.63% 71
2015
Q4 		– Sell
-490,747
Closed -$5.59M – 378
2015
Q3 		$5.59M Buy
+490,747
New +$6.55M 0.4% 94
2014
Q3 		– Sell
-626,013
Closed -$7.98M – 352
2014
Q2 		$7.98M Buy
+626,013
New +$6.09M 0.53% 79
2013
Q4 		– Sell
-386,089
Closed -$2.81M – 302
2013
Q3 		$2.81M Buy
+386,089
New +$1.96M 0.28% 122

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Bogle Investment Management's BCRX Position: Q2 2017 in Review

Bogle Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2017, closing a stake of 1,078,345 shares — an estimated $9.06M sold.

Bogle Investment Management first reported a position in BCRX in Q3 2013 and held it in 4 quarters. The position peaked at $9.06M in Q1 2017. 115 funds tracked by Wall St. Rank hold BCRX as of Q2 2017.

  • Bogle Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Bogle Investment Management sold 1,078,345 BioCryst Pharmaceuticals shares in Q2 2017, an estimated $9.06M.
  • Bogle Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • Bogle Investment Management's BioCryst Pharmaceuticals position peaked at $9.06M in Q1 2017.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2017.

Based on Bogle Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.